Substituted pyrazolopyrimidines as glucocerebrosidase activators
US-9353117-B2 · May 31, 2016 · US
Treatment of proteinopathies
US9845327B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9845327-B2 |
| Application number | US-201214127546-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 22, 2012 |
| Priority date | Jun 22, 2011 |
| Publication date | Dec 19, 2017 |
| Grant date | Dec 19, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides technologies relating to lysosomal activation. The disclosure provides several strategies for increasing level and/or activity of lysosomal enzyme, and furthermore demonstrates the surprising applicability of such strategies in the treatment and/or prophylaxis of certain proteinopathies. Among other things, the present invention provides methods and compositions for the treatment and/or prophylaxis of proteinopathies other than lysosomal storage diseases through lysosomal activation. In particular, the present disclosure provides methods and compositions for the treatment and/or prophylaxis of neurodegenerative proteinopathies, and in particular those associated with accumulation of α-synuclein. The present disclosure specifically provides methods and compositions for the treatment and/or prophylaxis of Parkinson's disease.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a neurodegenerative proteinopathic disease in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of the compound NCGC00188758 having the structure of Formula I: (Formula I), or a salt thereof, thereby to treat the neurodegenerative proteinopathic disease in the subject. 2. The method of claim 1 , wherein the disease is Parkinson's disease.
Assignees
Inventors
Classifications
for glucose homeostasis (pancreatic hormones A61P5/48) · CPC title
for hyperglycaemia, e.g. antidiabetics · CPC title
of the thyroid hormones, e.g. T3, T4 · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9845327B2 cover?
- The present disclosure provides technologies relating to lysosomal activation. The disclosure provides several strategies for increasing level and/or activity of lysosomal enzyme, and furthermore demonstrates the surprising applicability of such strategies in the treatment and/or prophylaxis of certain proteinopathies. Among other things, the present invention provides methods and compositions …
- Who is the assignee on this patent?
- Krainc Dmitri, Mazzulli Joseph R, Massachusetts Gen Hospital
- What technology area does this patent fall under?
- Primary CPC classification C07D487/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).